Cover Image
Market Research Report

Cholera Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)

Published by Mordor Intelligence LLP Product code 850165
Published Content info 114 Pages
Delivery time: 2-3 business days
Back to Top
Cholera Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)
Published: February 1, 2019 Content info: 114 Pages

Market Overview

The growth of the global cholera vaccines market can be attributed to multiple factors, such as the increasing incidences of cholera, rising initiatives by public and private entities, and growing awareness regarding cholera across the world. In 2017, 10 million doses of oral cholera vaccines were funded in affected countries via stockpile. This stockpile has been accessed 52 times since the funding, by 18 countries across the world, including Sierra Leone and Haiti. However, a lack of access to adequate care for cholera, coupled with a large number of unreported cases, are expected to pull back the growth of the market.

Scope of the Report

Cholera is caused by Vibrio cholerae via the consumption of contaminated food or water. The infected individuals suffer from severe watery diarrhea, eventually leading to dehydration, which if unattended, may lead to death, owing to access water loss. Oral vaccination has been observed to be the best preventive treatment for cholera and has proved to be very useful to prevent huge outbreaks. There are two basic types of vaccines given for cholera: whole-cell V. cholerae O1, in combination with a recombinant B-subunit of cholera toxin (WC/rBS), and killed oral O1 and O139.

Key Market Trends

Whole-cell V. cholerae O1 with a Recombinant B-subunit Segment Captures the Largest Market Share

This oral cholera vaccine containing a combination of recombinant B-subunit and killed the whole cell V. cholerae O1 has been marketed since early 1990. This vaccine is observed to provide 80-90% protection for six months, post immunization, and in all the cases of immunization of vaccines aged more than 2 years. In addition to this, this vaccines shows around 50% of protection even after three years of immunization. Hence, the efficacy and long-lasting post immunization protections of the vaccine are expected to propel the segment's growth over the forecast period.

North America is Expected to Grow at a High Rate over the Forecast Period

Asia-Pacific captures the largest market share in the global cholera vaccines market, followed by Europe. This can be attributed to the high incidence rate, growing awareness, and availability of efficient preventive solutions. The APAC market experienced exceptional growth since the launch of the oral cholera vaccine, Shanchol, in 2009. According to the statistics of WHO, 42 countries reported 172,454 cases of cholera in 2015, with 1,304 deaths. These statistics showed an overall decrease of 9% from the previous year, owing to growing immunization in the region. On the other hand, North America is expected to exhibit the fastest growth rate over the forecast period, owing to the launch of the first ever oral cholera vaccine, Vaxchora, in 2016, and the rise in the number of immigrants.

Competitive Landscape

Some of the significant companies in the market are AstraZeneca, Shantha Biotechnics Private Limited, Valneva SE, Merck & Co. Inc., and PaxVax Inc. The major market players, in order to retain a strong market position, focus on mergers, acquisitions, and product innovation. Also, licensing rights on the vaccines of some major companies give them the leverage of a strong market foothold. For instance, the licensing rights of Dukoral were conferred to Valneva SE, post-acquisition of Crucell Sweden AB, in turn, strengthening the company's cholera vaccine portfolio and overall market position.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support
Table of Contents
Product Code: 66036

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Incidences of Cholera
    • 4.2.2 Rising Initiatives and Awareness Regarding Immunization
  • 4.3 Market Restraints
    • 4.3.1 Lack of Access to Adequate Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 Vaccine Type
    • 5.1.1 Whole cell V. cholerae O1 with Recombinant B-subunit
    • 5.1.2 Killed Oral O1 and O139
  • 5.2 Product
    • 5.2.1 Vaxchora
    • 5.2.2 Dukoral
    • 5.2.3 Shanchol
    • 5.2.4 Other Products
  • 5.3 Geography
    • 5.3.1 North America
      • US
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • GCC
      • South Africa
      • Rest of Middle East & Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Astellas Pharma Inc.
    • 6.1.2 AstraZeneca
    • 6.1.3 Emergent BioSolutions Inc.
    • 6.1.4 GlaxoSmithKline plc (GSK)
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 Mitsubishi Tanabe Pharma Corporation
    • 6.1.7 PaxVax Inc.
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Shantha Biotechnics Private Limited
    • 6.1.10 Takeda Pharmaceutical Co. Ltd
    • 6.1.11 Valneva SE


Back to Top